Analysts Set Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) PT at $40.60

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) has been given an average rating of “Moderate Buy” by the eight ratings firms that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $39.83.

Several research firms have issued reports on DAWN. The Goldman Sachs Group dropped their target price on Day One Biopharmaceuticals from $50.00 to $44.00 and set a “buy” rating on the stock in a research report on Tuesday, February 27th. JPMorgan Chase & Co. increased their target price on Day One Biopharmaceuticals from $32.00 to $36.00 and gave the stock an “overweight” rating in a research report on Monday. Oppenheimer restated a “market perform” rating on shares of Day One Biopharmaceuticals in a research report on Tuesday, February 27th. Finally, Piper Sandler restated an “overweight” rating and set a $40.00 target price on shares of Day One Biopharmaceuticals in a research report on Tuesday, March 26th.

Insider Buying and Selling

In related news, insider Samuel C. Blackman sold 2,258 shares of the stock in a transaction on Friday, February 16th. The stock was sold at an average price of $15.25, for a total value of $34,434.50. Following the sale, the insider now owns 1,244,662 shares in the company, valued at $18,981,095.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other Day One Biopharmaceuticals news, insider Samuel C. Blackman sold 2,258 shares of the firm’s stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $15.25, for a total transaction of $34,434.50. Following the sale, the insider now owns 1,244,662 shares in the company, valued at $18,981,095.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Samuel C. Blackman sold 20,000 shares of the firm’s stock in a transaction dated Tuesday, February 27th. The shares were sold at an average price of $16.11, for a total value of $322,200.00. Following the sale, the insider now owns 1,224,662 shares in the company, valued at approximately $19,729,304.82. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 55,781 shares of company stock worth $883,160. Corporate insiders own 8.40% of the company’s stock.

Institutional Investors Weigh In On Day One Biopharmaceuticals

A number of large investors have recently added to or reduced their stakes in DAWN. China Universal Asset Management Co. Ltd. raised its position in Day One Biopharmaceuticals by 130.9% during the third quarter. China Universal Asset Management Co. Ltd. now owns 2,226 shares of the company’s stock valued at $27,000 after purchasing an additional 1,262 shares in the last quarter. Quest Partners LLC bought a new position in shares of Day One Biopharmaceuticals during the fourth quarter valued at about $29,000. Quintet Private Bank Europe S.A. grew its stake in shares of Day One Biopharmaceuticals by 43.2% during the fourth quarter. Quintet Private Bank Europe S.A. now owns 3,313 shares of the company’s stock valued at $48,000 after buying an additional 1,000 shares during the last quarter. Amalgamated Bank grew its stake in shares of Day One Biopharmaceuticals by 35.7% during the third quarter. Amalgamated Bank now owns 8,628 shares of the company’s stock valued at $106,000 after buying an additional 2,268 shares during the last quarter. Finally, Exchange Traded Concepts LLC grew its stake in shares of Day One Biopharmaceuticals by 34.0% during the fourth quarter. Exchange Traded Concepts LLC now owns 10,072 shares of the company’s stock valued at $147,000 after buying an additional 2,554 shares during the last quarter. Hedge funds and other institutional investors own 87.95% of the company’s stock.

Day One Biopharmaceuticals Stock Up 8.2 %

DAWN stock opened at $16.64 on Wednesday. The firm has a market cap of $1.45 billion, a PE ratio of -6.99 and a beta of -1.48. The business has a 50 day moving average of $15.27 and a 200-day moving average of $13.78. Day One Biopharmaceuticals has a 12-month low of $9.67 and a 12-month high of $17.85.

Day One Biopharmaceuticals (NASDAQ:DAWN) last announced its quarterly earnings data on Monday, February 26th. The company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.57) by ($0.07). On average, research analysts expect that Day One Biopharmaceuticals will post -2.66 earnings per share for the current year.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.